QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)
("**Company**")

COMPLETION OF SALE OF DRUG COATED PERIPHERAL PRODUCT TO G VASCULAR

---

*Capitalised terms used herein shall have the definitions ascribed to them in the Company's announcements dated 13 July 2020 and 27 August 2020 ("**Announcements**"), and circular dated 13 July 2020 ("**Circular**") in respect of the Proposed Disposal, unless otherwise stated or the context otherwise requires.*

The Board of Directors (the "**Board**") of the Company refers to the Announcements and the Circular, and wishes to update Shareholders that the Company has on 28 August 2020 completed the sale of the specific assets of the Group relating to the Drug Coated Peripheral Product to G Vascular Private Limited (the "**Proposed Disposal**") following the satisfaction of the conditions precedent in relation to the Proposed Disposal.

The Company shall make further announcements in relation to, *inter alia*, any material updates on the APA, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities. When in doubt, shareholders and potential investors are advised to seek independent advice from their bankers, stockbrokers, solicitors or other professional advisers.

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
30 August 2020

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg).
